Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03579446

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

49.1

Anticipated Duration (Months)

1.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.

Condition or Disease	Intervention/Treatment	Phase
Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm	Drug: Hydrocodone Drug: Hydromorphone Drug: Levorphanol Drug: Morphine Drug: Oxycodone Drug: Oxymorphone Other: Questionnaire Administration	Early Phase 1

Detailed Description

PRIMARY OBJECTIVE:

To determine the proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol at the primary end point.

SECONDARY OBJECTIVES:

To determine the median opioid rotation ratio (ORR) in patients undergoing successful opioid rotations from morphine equivalent daily dose (MEDD) to levorphanol in the Supportive Care Center (SCC) or Pain Clinic.
To determine the effect of levorphanol on cancer pain (as measured by change in Edmonton Symptom Assessment System's [ESAS] pain item from baseline) in cancer outpatients undergoing opioid rotation to levorphanol at the primary end point of treatment.
To determine the association between the opioid rotation ratio from MEDD to levorphanol and baseline MEDD prior to opioid rotation.
Measure levorphanol related side effects using the opioid side effect scale at day 10 +/- 1 of starting levorphanol.
Determine what percentage of patients rotated to levorphanol achieve their personalized pain goal.
Determine the predictors of successful opioid rotation from other opioids to levorphanol.

OUTLINE:

Patients receive levorphanol orally (PO) every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

86 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Supportive Care

Official Title:

Levorphanol as a Second Line Opioid in Cancer Patients Undergoing Opioid Rotation: An Open Label Study

Actual Study Start Date :

Nov 29, 2018

Anticipated Primary Completion Date :

Dec 31, 2022

Anticipated Study Completion Date :

Dec 31, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Supportive care (levorphanol, opioid regimen) Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.	Drug: Hydrocodone Given by PO Drug: Hydromorphone Given by PO Other Names: (-)-Hydromorphone Dihydromorphinone Hydromorphon Drug: Levorphanol Given PO Drug: Morphine Given by PO Drug: Oxycodone Given by PO Other Names: Oxycodone SR Drug: Oxymorphone Given by PO Other: Questionnaire Administration Ancillary studies

Arm

Intervention/Treatment

Experimental: Supportive care (levorphanol, opioid regimen)

Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.

Drug: Hydrocodone

Given by PO

Drug: Hydromorphone

Given by PO

Other Names:

(-)-Hydromorphone

Dihydromorphinone

Hydromorphon

Drug: Levorphanol

Given PO

Drug: Morphine

Given by PO

Drug: Oxycodone

Given by PO

Other Names:

Oxycodone SR

Drug: Oxymorphone

Given by PO

Other: Questionnaire Administration

Ancillary studies

Outcome Measures

Primary Outcome Measures

Proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol [Day 10 or any day after 2 days of rotation to levorphanol]
Bayesian methodology developed by Peter Thall will be used to monitor the study. This method decides whether levorphanol is promising relative to the standard medicine. Will estimate the proportion of successful opioid rotation along with a 95% confidence interval. Association between successful opioid rotation and demographic/clinical characteristics will be examined by Chi-squared test or Fisher's exact test when appropriate. Logistic regression model will be employed to assess the effect of demographic/clinical characteristics on the presence of successful opioid rotation.

Secondary Outcome Measures

Opioid rotation ratio (ORR) [Up to 30 days]
Will be calculated by levorphanol mg (day 10 +/- 1) over MEDD (day 0). ORR will be summarized using standard descriptive statistics such as mean, standard deviation, median and range. Wilcoxon rank-sum test or Kruskal-Wallis test will be applied to examine the difference on ORR between/among patients' characteristics groups.
Change of Edmonton Symptom Assessment Scale (ESAS) pain score [Baseline up to day 10 or any day after 2 days of rotation to levorphanol]
Pain score change will be summarized using standard descriptive statistics such as mean, standard deviation, median and range. Wilcoxon rank-sum test or Kruskal-Wallis test will be applied to examine the difference on pain score change between/among patients' characteristics groups. Since ESAS pain score will be measured daily from day 0 to day 10 +/- 1 and on day 30 +/- 3, mixed model will be applied to examine the differential changes over time for ESAS pain score, adjusting for other covariates of interest. ORR and baseline MEDD will be presented by scatter plots. Correlation will be assessed between levorphanol dose on day 10 +/- 1, ORR and baseline MEDD suing Pearson or Spearman correlation coefficient when appropriate. Linear regression models will be applied to estimate the linear association between levorphanoal dose on day 10 +/- 1, ORR and baseline MEDD.
Incidence of levorphanol related side effects [Up to day 30]
Will be rated using the Opioid Side Effect Scale on xerostmia, nauseas, constipation, drowsiness and confusion daily from day 0 to day 10 +/-1 and on day 30 +/- 3.
Personalized pain goal (PPG) [Up to day 30]
PPG will be summarized using standard descriptive statistics such as mean, standard deviation, median and range. Mixed model will be applied to examine the differential changes over time for opioid side effect scale, adjusting for other covariates of interest. The goal is not achieved if the PPG is lower than the ESAS pain score. Frequency and proportion of achieved goal will be summarized.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients seen in the SCC or Pain Clinic with a diagnosis of cancer with or without evidence of metastatic disease
Diagnosis of cancer related pain currently treated with first line strong oral opioid analgesics such as morphine, oxycodone, oxymorphone, hydromorphone or hydrocodone
Age 18 or older
Able to complete study assessments
Individual is willing to sign written informed consent
Patients who are classified as being opioid tolerant by receiving a baseline MEDD of

= 60 mg

Patients who are local and able to follow-up in the SCC or Pain Clinic within 30 days if necessary
Eastern Cooperative Oncology Group (ECOG) performance status of =< 3

Exclusion Criteria:

Cognitive impairment with a Memorial Delirium Assessment Scale (MDAS) score of 7 or higher or diagnosed with neurocognitive impairment by the treating SCC or Pain Clinic physician
Renal insufficiency defined as estimated glomerular filtration rate of < 60
Hepatic insufficiency defined as transaminitis (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] > 3 times the highest normal value) or hyperbilirubinemia of > 1.5 times the highest normal value
Non-English speaking participants as not all assessments are validated in other languages
Presence of neuropathic pain as a primary pain syndrome
Non-malignant pain
Patients with history of alcohol or substance abuse by using Cut-down, Annoyed, Guilty, Eye-opener adapted to include Drug use questionnaire (CAGE-AID) score of 2 or higher; Pain Clinic: Screener and Opioid Assessment for Patients with Pain (SOAPP) score of 7 or higher. In the unlikely event that CAGE-AID or SOAPP is not present in patient's chart, a CAGE-AID questionnaire will be administered after obtaining verbal consent for screening
Patients receiving methadone due to reasons such as long and variable half-life
Patients receiving scheduled benzodiazepines due to the risk of excessive sedation
Patients with a MEDD of > 300
Unable or unwilling to sign consent